Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.

PLoS Negl Trop Dis · 2019 · PMC6716679 · PMID 31430284

Europe PMC DOI

hedged sentence

0.2600

closest p · 5.2× alpha

0.2600

boldest claim

The sentences

did not reach statistical significancep = 0.26not close (p > 0.1)

pestis challenge prime-boost although this survival rate did not reach statistical significance ( p = 0.26) compared to the unvaccinated (PBS) control.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.